Sign In
Buy KYTX
$7.82
-0.0800 (-1.01%)
At Close: Jun 03, 2026
Kyverna Therapeutics to Host Conference Call on Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis
08:00am, Wednesday, 22'nd Oct 2025
EMERYVILLE, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoi
NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- What's Happening: Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therap
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved expanded disability status scale scores (EDSS)
Kyverna Therapeutics to Highlight Interim Phase 2 Data from KYV-101 KYSA-6 Study in Myasthenia Gravis at AANEM 2025
01:02pm, Monday, 15'th Sep 2025
Oral presentation to include topline efficacy and safety data for 6 patients with up to 9 months of follow up
KYV-101 has the potential to deliver durable, drug-free, disease-free remission in myasthenia gravis and set a new treatment standard for stiff person syndrome
Kyverna Therapeutics to Present at Upcoming Investor Conferences in September
04:02pm, Monday, 25'th Aug 2025
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with auto
Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
03:29pm, Wednesday, 20'th Aug 2025
The biotechnology sector is experiencing a surge in innovation as companies develop advanced therapies to address complex diseases. This wave of progress is particularly evident in the development of
Kyverna Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
04:02pm, Tuesday, 12'th Aug 2025
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) and BLA submission anticipated in 1H 2026
Kyverna Therapeutics to Host Virtual KOL Event to Highlight Neuroimmunology CAR T Franchise
08:30am, Tuesday, 29'th Jul 2025
Webcast to be held August 28, 2025, 11:00am ET EMERYVILLE, Calif. , July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASD
Squarepoint Ops LLC Acquires New Holdings in Kyverna Therapeutics, Inc. (NASDAQ:KYTX)
03:34am, Wednesday, 11'th Jun 2025
Squarepoint Ops LLC acquired a new stake in Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm
Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference
04:02pm, Wednesday, 28'th May 2025
EMERYVILLE, Calif. , May 28, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. (Kyverna, Nasdaq: KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with
NEW YORK, May 15, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Kyverna Therapeutics, Inc. (NASDA
Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results
04:02pm, Tuesday, 13'th May 2025
Enrollment complete in registrational Phase 2 KYV-101 trial in stiff person syndrome (SPS); on track for topline data in 1H 2026; biologics license application (BLA) filing now anticipated in 1H 2026�
Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
04:02pm, Thursday, 27'th Mar 2025
Accelerating clinical path to commercialization in stiff person syndrome, myasthenia gravis and lupus nephritis Aligned with the U.S. Food and Drug Administration (FDA) on a registrational Phase 2 tri
